For the quarter ending 2025-09-30, FENC had $3,242K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss)/income | -637 | -4,317 |
| Inventory reserve | -517 | - |
| Allowance for credit losses | -1,155 | 1,222 |
| Amortization of debt discount | 12 | 26 |
| Loss on securities | 0 | 2 |
| Amortization of norgine asset | 26 | 51 |
| Stock-based compensation - employees | 2,219 | 2,292 |
| Accounts receivable | 3,440 | 5,542 |
| Prepaid expenses | -3,340 | 1,659 |
| Inventory | 276 | 1,141 |
| Other assets | -520 | 435 |
| Accounts payable | -75 | 2,700 |
| Accrued liabilities | 1,476 | -1,203 |
| Net cash (used in) / provided by operating activities | 1,493 | -8,004 |
| Issuance of shares, options exercise | 1,799 | 186 |
| Cash paid for taxes on restricted share release | 50 | 111 |
| Net cash provided by / (used in) financing activities | 1,749 | 75 |
| (decrease) / increase in cash and cash equivalents | 3,242 | -7,929 |
| Cash and cash equivalents at beginning of period | 26,634 | - |
| Cash and cash equivalents at end of period | 21,947 | - |
FENNEC PHARMACEUTICALS INC. (FENC)
FENNEC PHARMACEUTICALS INC. (FENC)